Jubilant Ingrevia Ltd

Jubilant Ingrevia has faced a notable decline in stock performance, losing 5.01% on February 14, 2025, and continuing a downward trend with a cumulative drop of 15.11% over the past five days. The stock is trading below multiple moving averages, indicating persistent challenges in the market.

Jubilant Ingrevia has reported its financial results for the quarter ending December 2024, highlighting strong performance in key metrics. The operating profit to interest ratio reached a record high, while profit before tax and profit after tax saw significant increases. However, the debtors turnover ratio declined, indicating slower debt settlement.

Jubilant Ingrevia, a midcap pharmaceuticals player, rebounded on January 23, 2025, after six days of declines, outperforming its sector. The stock is above its 200-day moving average but below shorter-term averages, reflecting mixed trends. Over the past month, it has declined more than the Sensex.

Jubilant Ingrevia has recently undergone a revision in its score, reflecting its current market challenges. Despite a notable decline in performance, the stock remains above key moving averages, indicating some resilience. Additionally, it has been added to MarketsMOJO's list, highlighting its potential amidst recent fluctuations.

Jubilant Ingrevia has experienced a revision in its stock evaluation following a notable decline in performance. Despite a recent drop, the stock has shown resilience over the past month, outperforming broader market indices. Additionally, it has been added to MarketsMOJO's list, indicating ongoing interest from analysts.

Jubilant Ingrevia has recently been added to MarketsMOJO's list following a revision in its score, reflecting its strong market performance. The stock has reached an all-time high, outperforming its sector and demonstrating significant growth over the past year, highlighting its robust position in the pharmaceutical industry.

Jubilant Ingrevia has recently experienced a revision in its score, reflecting its strong market performance and resilience in the pharmaceutical sector. The stock has been added to MarketsMOJO's list, underscoring its positive trajectory, as it consistently trades above key moving averages and outperforms the broader market indices.

Jubilant Ingrevia has recently been added to MarketsMOJO's list following a revision in its score, reflecting its strong market performance. The stock reached a 52-week high, outperforming its sector and demonstrating consistent gains. Investors are encouraged to keep an eye on this midcap pharmaceutical company's promising trajectory.

Jubilant Ingrevia has been added to MarketsMOJO's list following a recent adjustment in its evaluation. The stock has demonstrated robust performance, trading near its 52-week high and outperforming the sector. This marks a positive trend, with consistent gains over the past few days, reflecting strong market positioning.

Jubilant Ingrevia, a midcap pharmaceutical company, saw a 5.07% increase in its stock price on November 29, 2024, outperforming the sector by 2.77%. With a 'Hold' recommendation from MarketsMOJO, the company's consistent trading above its moving averages and positive growth in the pharmaceutical sector make it a promising stock to watch.

Jubilant Ingrevia, a midcap pharmaceutical and drugs company, saw a 5.16% increase in its stock performance on November 26, 2024, outperforming the sector by 5.24%. The stock has been on a consecutive gain for the last 5 days, with a rise of 12.65%, and is currently trading higher than its moving averages. In comparison to the Sensex, Jubilant Ingrevia has consistently shown better performance in the last 1 day and 1 month.

Jubilant Ingrevia, a midcap pharmaceutical and drugs company, has seen a 5.34% increase in its stock price on November 25th, 2024. The stock has been on a consecutive gain for the last 4 days and has outperformed its sector by 4.33%. Moving averages indicate a positive trend and the stock has also outperformed the Sensex in the last month.

Jubilant Ingrevia, a midcap pharmaceutical and drug company, experienced a -5.23% decline in its stock price on October 24, 2024. This was reflected in the stock's day's low of Rs 669, which was -5.51% lower than the previous day's closing price. The stock's current call is 'Hold' according to MarketsMOJO, with a -5.92% underperformance compared to the sector. However, the stock's moving averages are still higher than the 100 day and 200 day averages, indicating a positive long term trend. In comparison to the overall market, Jubilant Ingrevia's stock saw a -4.52% decline, significantly lower than the Sensex's -0.09% decrease. Over the past month, the stock has seen a -10.88% decline, while the Sensex only decreased by -5.78%. Investors are advised to conduct their own research and seek professional advice before making any investment decisions.

Jubilant Ingrevia, a midcap pharmaceutical company, has reported a flat performance for the quarter ending September 2024, with a score of 5. However, the company's operating profit and profit after tax have shown positive trends, while the operating cash flow and non-operating income need improvement. MarketsMOJO has given a 'Hold' call for the company's stock.

Jubilant Ingrevia, a midcap pharmaceutical company, saw a -5.22% decline in its stock price on October 22, 2024. Despite outperforming the sector, the stock has been on a consecutive fall for the last two days, with a total decline of -8.05%. Investors should monitor its performance in the coming days.

On October 16th, 2024, Jubilant Ingrevia, a midcap pharmaceutical and drugs company, gained 5.18% and closed at Rs. 783.75. It outperformed the sector by 5.72% and has been on a consecutive gain for the last 2 days. The stock is currently trading above its moving averages and has shown a strong performance compared to the Sensex.

On October 7th, 2024, Jubilant Ingrevia, a midcap pharmaceutical and drugs company, saw a -5.6% decline in its stock and has been given a 'Hold' rating by MarketsMOJO. The stock opened with a 3.02% gain but underperformed the sector by -5.84%. It is currently trading higher than its moving averages but lower than its 5-day and 20-day averages. In comparison to the Sensex, the stock's 1-day performance is -5.97%. Investors are advised to monitor the stock's movement and market trends before making any investment decisions.

Jubilant Ingrevia, a midcap pharmaceutical and drugs company, reached a 52-week high of Rs. 818.25 on October 3rd, outperforming the sector by 5.2%. The stock has been gaining for the past three days with a 9.82% increase in returns. It is currently trading higher than its moving averages, showing potential for investors.

On October 3rd, 2024, Jubilant Ingrevia's stock price rose by 5.05%, reaching a new 52-week high of Rs.818.25. This was accompanied by a 'Hold' call from MarketsMOJO. The company has outperformed the sector by 5.2% and has been gaining for the last three days, with a total return of 9.82%. It also has a positive trend, trading higher than its moving averages. However, it experienced high volatility with an intraday volatility of 6.14%.